Publikationen in Zusammenarbeit mit Forschern von Aarhus University Hospital (19)

2022

  1. Romosozumab efficacy and safety in European patients enrolled in the FRAME trial

    Osteoporosis International, Vol. 33, Núm. 12, pp. 2527-2536

2019

  1. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 12, pp. 899-911

  2. Reduction of Hip and Other Fractures in Patients Receiving Teriparatide in Real-World Clinical Practice: Integrated Analysis of Four Prospective Observational Studies

    Calcified Tissue International, Vol. 104, Núm. 2, pp. 193-200

2018

  1. Effects of Teriparatide in Patients with Osteoporosis in Clinical Practice: 42-Month Results During and After Discontinuation of Treatment from the European Extended Forsteo® Observational Study (ExFOS)

    Calcified Tissue International, Vol. 103, Núm. 4, pp. 359-371

  2. Real-world effectiveness of teriparatide on fracture reduction in patients with osteoporosis and comorbidities or risk factors for fractures: Integrated analysis of 4 prospective observational studies

    Bone, Vol. 116, pp. 58-66

2017

  1. Effect of Teriparatide or Risedronate in Elderly Patients With a Recent Pertrochanteric Hip Fracture: Final Results of a 78-Week Randomized Clinical Trial

    Journal of Bone and Mineral Research, Vol. 32, Núm. 5, pp. 1040-1051

  2. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial

    The Lancet, Vol. 390, Núm. 10102, pp. 1585-1594

2016

  1. Effects of teriparatide compared with risedronate on recovery after pertrochanteric hip fracture results of a randomized, active-controlled, double-blind clinical trial at 26 weeks

    Journal of Bone and Joint Surgery - American Volume, Vol. 98, Núm. 22, pp. 1868-1878

  2. Effets du tériparatide et du risédronate sur la DMO et la consolidation fracturaire chez des patients âgés avec fracture pertrochantérique récente: Résultats finaux d'un essai clinique randomisé de 78 semaines

    Revue du Rhumatisme (Edition Francaise), Vol. 83, pp. A83-A84

  3. Fracture Rate, Quality of Life and Back Pain in Patients with Osteoporosis Treated with Teriparatide: 24-Month Results from the Extended Forsteo Observational Study (ExFOS)

    Calcified Tissue International, Vol. 99, Núm. 3, pp. 259-271

  4. Fracture rate, back pain and quality of life in patients with osteoporosis treated with teriparatide: Results of the European observational study ExFOS (Extended Forsteo® Observational Study)

    Revue du Rhumatisme (Edition Francaise), Vol. 83, pp. A188-A189

2013

  1. Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: The European Forsteo Observational Study

    BMC Musculoskeletal Disorders, Vol. 14

2012

  1. Effectiveness of teriparatide in postmenopausal women with osteoporosis and glucocorticoid use: 3-Year results from the EFOS study

    Journal of Rheumatology, Vol. 39, Núm. 3, pp. 600-609

  2. Effectiveness of teriparatide in women over 75 years of age with severe osteoporosis: 36-month results from the European Forsteo Observational Study (EFOS)

    Calcified Tissue International, Vol. 90, Núm. 5, pp. 373-383

  3. Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study

    European Journal of Endocrinology, Vol. 166, Núm. 1, pp. 87-97

2011

  1. Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS)

    Osteoporosis International, Vol. 22, Núm. 10, pp. 2709-2719

2009

  1. Reduction in fracture rate and back pain and increased quality of life in postmenopausal women treated with teriparatide: 18-month data from the European Forsteo Observational Study (EFOS)

    Calcified Tissue International, Vol. 85, Núm. 6, pp. 484-493

  2. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: An analysis by gender and menopausal status

    Osteoporosis International, Vol. 20, Núm. 12, pp. 2095-2104

2008

  1. Characterization of patients in the European Forsteo Observational Study (EFOS): Postmenopausal women entering teriparatide treatment in a community setting

    Current Medical Research and Opinion, Vol. 24, Núm. 2, pp. 377-384